

Awake Prone Positioning in the Management of COVID-19 Pneumonia: A Systematic Review

Geetanjali T Chilkoti¹, Medha Mohta², Ashok K Saxena³, Zainab Ahmad⁴, Chhavi S Sharma⁵

ABSTRACT

Background: The aim was to investigate the efficacy of prone positioning (PP) in the management of coronavirus disease-2019 (COVID-19) pneumonia in various setups, with various modes of oxygen therapy and its optimal duration.

Materials and methods: A systematic literature search was conducted from inception until May 15, 2021. Patients with a validated diagnosis of COVID-19 and receiving PP were included. Various factors, including intensive care unit (ICU) or non-ICU setup, mode of oxygen therapy, outcome, duration of proning, and limitations, were noted.

Results: We retrieved 36 articles with a total of 1,385 patients for qualitative analysis. Out of 36 articles, there were 17 original articles, 09 case series, and 10 case reports. Out of 1,385 participants, 78.9% ($n = 1,093$) and 21.0% ($n = 292$) of patients were managed in ICU and non-ICU setup, respectively. Awake PP with high flow nasal cannula (HFNC) was found to be a promising technique; however, the result was inconclusive with helmet continuous positive airway pressure (CPAP). No study has evaluated the optimal duration of awake PP and the associated long-term outcomes.

Conclusion: We encourage the use of early awake self-proning in the management of COVID-19 disease. However, the evidence in terms of its use in non-ICU setup, the optimal duration of PP, and various oxygenation devices are insufficient, thereby mandating further well-designed multicentric studies to evaluate its efficacy as an adjunct in the management of COVID-19 pneumonia in context to the aforementioned factor.

Keywords: COVID-19 pneumonia, Management, Prone positioning.

Indian Journal of Critical Care Medicine (2021): 10.5005/jp-journals-10071-23932

INTRODUCTION

Prone positioning (PP) has been an established technique for improving oxygenation in severe acute respiratory distress syndrome (ARDS).¹⁻³

Considering the proven benefits of PP in intubated patients, physiologically, it was also assumed to benefit awake, nonintubated patients with acute hypoxemic respiratory failure. With the recent coronavirus disease-2019 (COVID-19) surge, awake self-PP has been practiced widely in the treatment of moderate to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. It is a low-risk intervention requiring minimal assistance and, therefore, has also been applied outside the intensive care unit (ICU). Recently, the UK Intensive Care Society has also advocated awake PP as a standard of care for suspected or confirmed COVID-19 patients requiring a $\text{FiO}_2 \geq 28\%$.⁴ However, Chad et al. in a review implicated this short-term improvement in oxygenation with PP to be simply a "recruitment maneuver," which could have been efficacious in only patients with less severe disease.⁵ In addition, the patient population assessed in various studies evaluating awake PP in SARS-CoV-2 is heterogeneous in terms of the severity of illness, mode of oxygen therapy, ventilatory status, treatment protocol, mean duration of proning, and the setting, that is, ICU or non-ICU.

As COVID-19 is a novel viral disease, and the evidence available so far to support the efficacy of awake PP is limited; this systematic review was conducted to investigate its efficacy in both awake and intubated patients as an adjunct along with different modes of oxygen therapy or respiratory support, its performance in different setups, that is, ICU or non-ICU, and also the optimal duration of PP.

¹⁻⁵Department of Anaesthesiology, University College of Medical Sciences, New Delhi, India

Corresponding Author: Geetanjali T Chilkoti, Department of Anaesthesiology, University College of Medical Sciences, New Delhi, India, Phone: +91 09711210772, e-mail: geetanjaliidr@yahoo.co.in

How to cite this article: Chilkoti GT, Mohta M, Saxena AK, Ahmad Z, Sharma CS. Awake Prone Positioning in the Management of COVID-19 Pneumonia: A Systematic Review. *Indian J Crit Care Med* 2021;25(8):896-905.

Source of support: Nil

Conflict of interest: None

LITERATURE SEARCH AND DATA SOURCE

We conducted a comprehensive literature search using PubMed, MEDLINE, Embase, and Google Scholar from December 2019 to May 15, 2020. In PubMed, the following search strategy was used: "(COVID-19 OR Novel Coronavirus-Infected Pneumonia OR 2019 novel coronavirus OR SARS-CoV-2) AND (prone oxygenation OR awake prone position OR self proning)." The strategy was then further adapted for other databases. The titles and abstracts were reviewed to evaluate their relevance to our study. Full-text articles were retrieved for further consideration for inclusion. Two authors (G.T.C. and M.M.) read all the articles, and any inconsistencies were resolved by consensus with the third author (A.K.S.).

Study Selection-For study selection, we followed PICO framework: participants, who had a validated diagnosis of COVID-19, irrespective of stage or severity of disease; intervention, oxygen therapy or respiratory support in awake self-PP; comparison, patients not receiving prone oxygenation,

if original article; outcomes, various parameters indicating oxygenation. A priori, both interventional and observational data were considered.

Data Extraction—No language restriction was imposed, in order to include maximum articles and minimize language bias. For each article, we extracted data regarding authors, year of publication, the period of observation, patient selection, ICU or non-ICU setting, duration of PP, outcomes assessed, conclusion, and limitations, if any. For the present systematic review, due to the novel nature of the disease, all kinds of publications, that is, case report, case series, editorials, letters, and reviews in addition to original articles providing evidence toward the efficacy of awake PP in the improvement of oxygenation in COVID-19 disease, were included.

RESULTS

Flowchart 1 shows the PRISMA flowchart depicting the qualitative synthesis of evidence from the literature search. Following the screening of titles, abstracts, and removal of duplicates, finally, we included 36 articles with a total of 1,385 patients for qualitative analysis. Out of 36, 17 were original articles,^{6–22} nine case series,^{23–31} and 10 case reports.^{32–41} In addition, there were seven protocols,^{42–48} seven reviews,^{49–55} two commentaries,^{21,56} and four editorial.^{57–60} The 17 original articles were included in the qualitative assessment of risk of bias. All the included articles were published from the inception of COVID-19 till May 15, 2021.

Table 1 shows the characteristics of all the clinical studies evaluating PP in COVID-19 pneumonia.

Awake PP in COVID-19 Pneumonia in Non-ICU Setup

Out of all the articles, six studies have evaluated awake PP used outside the ICU for COVID-19 pneumonia.^{6,7,10,14,19,22} Caputo et al. applied PP to 50 COVID-19 patients in the Emergency Department and showed a significant improvement in oxygenation.⁶ A one-day cross-sectional, before-after study was conducted by Sartini et al. on 15 awake non-ICU patients on noninvasive ventilation (NIV) irrespective of the day. They recorded SpO₂, PaO₂/FiO₂, respiratory rate (RR), and patients' comfort at three designated

time points while receiving NIV in PP, that is, before starting NIV, 60 minutes after the start of PP, and 60 minutes after the end of NIV. A significant improvement in SpO₂ and PaO₂/FiO₂ from 100 (IQR, 60–112) to 122 (IQR, 118–122) (*p* < 0.001 for both) along with a decrease in RR during NIV in PP was observed. On follow-up at day 14, nine patients were discharged, one improved, one was intubated, and one died.¹⁰

On the contrary, Elharrar et al. in a single-center, before-after study, in patients receiving NIV, observed that out of 24, PaO₂ improved in only six patients, that is, merely 25% with PP, whereas four patients did not tolerate PP for more than an hour and required intubation.⁷

Awake PP in COVID-19 Pneumonia in ICU Setup

Out of all the studies conducted in ICU, only Zang et al.¹³ had incorporated a control group and compared the oxygenation status of patients receiving PP with the ones who did not receive it. The oxygenation parameters used were SpO₂, RR, and ROX index. They did not compare the PaO₂/FiO₂ ratio, and also the number of patients with severe diseases was limited in their study.

In another study, Tu et al. exclusively enrolled nine patients with COVID-19 on flow nasal cannula (HFNC) for more than 2 days and having PaO₂/FiO₂ < 150 mm Hg. Prone position was found to be efficacious in improving oxygenation in patients on HFNC.⁸

Similarly, Coppo et al.,⁹ in a prospective cohort study, assessed the feasibility of PP in 56 patients receiving NIV or conventional oxygen therapy (COT) and found it to be feasible in 83.9% of patients (*n* = 47). Oxygenation improved PaO₂/FiO₂ ratio from 180.5 to 285.5 mm Hg (112.9) in PP (*p* < 0.0001). Oxygenation following resupination was maintained in only 23 patients (50%). It was concluded that PP was feasible and effective in improving oxygenation in awake patients with COVID-19; however, the effect was sustained in only 50% of patients.

Thompson et al.¹¹ in a cohort study on 25 patients also observed the efficacy of PP in improving the oxygenation and its effects on intubation rate. They observed that 1 hour after

Flowchart 1: PRISMA flowchart depicting the steps of qualitative synthesis of evidence from the literature




Table 1: Characteristics of the published clinical studies evaluating PP in patients with COVID-19 pneumonia⁶⁻²²

| Authors | Type of study | Set-up | N (number of patients) | Age (years) | Initiation of therapy/ mode of oxygen therapy | Outcome | Duration of proning | Conclusion | Limitations |
|-------------------------------|--|---------|---|--|--|--|--|---|---|
| Caputo et al. ⁶ | Observational cohort | Non-ICU | 50 | 59 (IQR 50-68) | SpO ₂ <90% and NRBIM or nasal cannula | Change in median SpO ₂ after 5 min of PP; rate of intubation in patients who were prone | Parameters evaluated after 5 min of PP | Median SpO ₂ increased to 94% from 84% (IQR, 75-90%) after 5 min of PP; 24% (n = 13) required intubation | Nonexperimental sequential case series; Treatment protocols were not controlled; single center study |
| Elharrar et al. ⁷ | Prospective, single center, before and after study | Non-ICU | 24 | 66.1 (10.2) | Requiring oxygen supplementation and CT scan suggestive of COVID-19 | Proportion of patients showing increase in PaO ₂ by > 20% after PP; feasibility, that is, proportion of patients sustaining PP ≥ 1 hr and ≥ 3 hr | 1-3 hr | 63% able to tolerate PP beyond 3 hr; 21% tolerated it 1-3 hr and 17% tolerated <1 hr Patients who sustained PP for 3 hr had increase in PaO ₂ from a mean of 73.6 (SD, 15.9 mm Hg) before PP to 94.9 (SD, 28.3 mm Hg) during PP [difference, 21.3 (95% CI, 6.3-36.3) mm Hg; p = 0.006] | Small sample size; short follow-ups; clinical outcomes were not assessed |
| Tu et al. ⁸ | Pilot study | ICU | 9 | 51 ± 11 | Patients on HFNC for >2 days with PaO ₂ /FIO ₂ <150 mm Hg | Improvement in SpO ₂ ; mean PaO ₂ | 2 hr (IQR, 1-4 hr) | SpO ₂ —increased from 90 ± 2 to 96 ± 3% (p <0.001), mean PaO ₂ increased from 69 ± 10 to 108 ± 14%, and PaCO ₂ decreased from 47 ± 7 to 39 ± 5 mm Hg (p = 0.007) | Small sample size; lack of control group |
| Coppo et al. ⁹ | Single center, prospective cohort, feasibility study | ICU | 56 | 57.4 (7.4) | Patients on either NIV or COT | PaO ₂ /FIO ₂ at 10 min after PP and 1 hr after respiration; safety, feasibility, PaCO ₂ | 3 hr | PaO ₂ /FIO ₂ ratio increased after PP, and improved oxygenation was maintained in 23 patients (50%) patients after respiration. PP was feasible (i.e., PP maintained for at least 3 hr) in 47 patients (83.9%) | Lack of control group; selection bias; single-center data |
| Sartini et al. ¹⁰ | Cross-sectional, before/after study | Non-ICU | 15 | 59 (6.5) | Patients on NIV | SpO ₂ , PaO ₂ /FIO ₂ , RR, and patients' comfort were assessed at three time points while on NIV in PP; that is, baseline, at 60 min after starting NIV, and 60 min of end of NIV session | Median number of NIV cycles in the PP was 2 (IQR, 1-3 cycles) for a total duration of 3 hr (IQR, 1-6 hr) | Significant reduction in RR during and after pronation (p <0.001 for both); significant improvement in SpO ₂ and PaO ₂ /FIO ₂ during pronation (p <0.001 for both) in all; improvement in SpO ₂ and PaO ₂ /FIO ₂ after pronation in 12 patients (80%); unchanged in 2 (13.3%); and worsened in 1 (6.7%) | Small sample size; short duration of NIV in prone; no control group |
| Thompson et al. ¹¹ | Single-center, cohort study | ICU | 29 eligible, but PP in 25 patients | Intubated-67 (45-71) and Nonintubated-66.0 (53-87) | Severe hypoxemic ARF on either nasal cannula or NRBIM | SpO ₂ before and 1 hr after initiating PP; intubation rate | At least one session in a day of more than 1 hr | Improvement in SpO ₂ from supine to 1 hr postproning was 1-3.4% (median [SE], 7% [1.2%]; 95% CI, 4.6-9.4%); the mean difference in intubation rate among patients with SpO ₂ of 95% or greater vs SpO ₂ less than 95% 1 hr after initiation of PP was 46% (95% CI, 10-88%) | Small sample size; no control group |
| Retucci et al. ¹² | Pilot, observational, prospective study | ICU | 26 | 62 (IQR, 56-69) | Patients on helmet CPAP treatment with PaO ₂ /FIO ₂ ratio <250 for more than 48 hr | A decrease in the A-a O ₂ gradient of at least 20%; equal or reduced RR and dyspnea; SBP ≥90 mm Hg | 1 hr | Among trials conducted in PP, 33.3% succeeded; 41.7% showed decreased A-a O ₂ (<20%), and 25% failed. Among trials conducted in lateral positioning, 8% succeeded; 52% showed decreased A-a O ₂ (<20%), and 40% failed. High failure rate was reported. | Did not assess the clinical outcome; evaluation of both response and tolerance to both positionings conducted only after 1 hr |
| Zang et al. ¹³ | Single center, cohort study | ICU | 60 patients enrolled. PP—23 and Non-PP—37 | 62 | Moderate hypoxemia and on High FIO ₂ reservoir mask with SpO ₂ <93% | SpO ₂ , RR, ROX index at 10 min and 30 min after PP | Mean duration of PP per patient was 13 hr | Significant difference in SpO ₂ -10 min, ROX 10 min, SpO ₂ -30 min, RR30 min, and ROX index:30 min between the two groups (p <0.01). On 90 days follow-up, 43.5 and 76% in PP and non-PP group died, respectively | PaO ₂ /FIO ₂ was not analyzed; limited number of severe disease patients were enrolled |



| Author | Study Design | Setting | Non-ICU | ICU | Sample Size | Intubation rate, mortality | Nonintubated patients | Intubation rate, mortality | >1 hr for 5 times/day | 38.1% required intubation, lower mortality | Variability in PP |
|-------------------------------|---|---------|--|-----|--------------------------------------|--|---|--|-----------------------|--|---|
| Jagan et al. ¹⁴ | Retrospective study | Non-ICU | 105 | | 56.0 ± 14.4 | Intubation rate, mortality | Nonintubated patients | >1 hr for 5 times/day | | 38.1% required intubation, lower mortality | Variability in PP |
| Hallifax et al. ¹⁵ | Retrospective study | ICU | 48 | | 69 (54–80) | Patients discharged, Shifting to ICU | Patients on CPAP/HFNC | >2 hr, twice daily for at least 2 days | | 22.9% discharge, 22.9% ICU admission, 62.5% of patients on CPAP tolerated awake PP | Awake PP more feasible with CPAP than HFNC |
| Singh et al. ¹⁶ | Retrospective study | ICU | 95 | | 51.5 | P/F ratio, SpO ₂ | Patients with SpO ₂ >90% through simple face mask, NRBM, NIV | 10–12 hr/day | | Marked increase in P/F ratio and SpO ₂ | Small sample size |
| Khanum et al. ¹⁷ | Observational study | ICU | 23 | | 54.5 (11.7) | Avoidance of intubation, mortality | Oxygen therapy with or without NIV | No prefixed targeted duration but >1 day | | Only one patient required intubation, rest 22 improved | Small sample size, no fixed duration of PP |
| Syama et al. ¹⁸ | Prospective interventional study | ICU | 45 cases = 30 Control = 15 | | 53.1 (11) | Intubation rate and ROX index at 30 min, 12 hr | All patients with room air saturation <93% | 7.5 hr on day 1 | | Increased intubation rate in control group (33.1 vs 6.7%) ROX index increased in cases [10.7(3.8) vs 6.7 (2.6), p <0.001] | Nonrandomized, P/F ratio not measured |
| Kharat et al. ¹⁹ | Cluster RCT | Non-ICU | 27 (Control = 17, cases = 10) | | Control (58 ± 12) Cases = 54 ± 14 | Oxygen flow requirement | Patients on low flow oxygen therapy | 12 hr/day | | Oxygen flow requirement was less in PP group [1 (0.1–2.9) L/min vs 2.0 (0.5–3) L/min] | Intervention and assessment both were limited to 24 hr time frame |
| Tonelli et al. ²⁰ | Retrospective multicentric cohort | ICU | 114 (standard treatment = 76, PP = 38) | | PP = 61 Standard treatment = 70 | Intubation rate | Patients on NIV | 3 hr (1–4 sessions/day) | | Reduced intubation rate with PP (18 vs 39.5%) | Different SOPs in both centers; duration of proning was variable |
| Nauka et al. ²¹ | Nested case matched control analysis | ICU | 600 (200 cases, 400 control) | | Comparable between two groups | Rate of IMV or mortality | All nonintubated patients | Cases were maintained on nonintubated proning for less time [time difference was 39.2 hr (IQR, 0–88.9 hr)] | | Nonintubated proning did not alter intubation rate but temporarily improved hypoxemia | Heterogenous patients, adherence to PP |
| Dubosh et al. ²² | Prospective, observational cohort study | Non-ICU | 22 | | 61 (IQR: 50, 65) | 109 (IQR: 65, 159) min | Patients on oxygen via nasal cannula or NRBM | SpO ₂ /FiO ₂ ratio, RR | | SpO ₂ /FiO ₂ ratio increased with PP [median: 298 (IQR: 263–352) vs 295 (IQR: 276–350), p = 0.01] | Small sample size |

N, number of patients; PP, prone positioning; NRBM, non-rebreathing mask; HFNC, high flow nasal cannula; A-a O₂ gradient, alveolar-arterial gradient; RR, respiratory rate; SBP, systolic blood pressure; CPAP, continuous positive airway pressure; COT, conventional oxygen therapy; NIV, noninvasive ventilation; RR, respiratory rate; VV-ECMO, Veno-venous extracorporeal membrane oxygenation; ROX index, ratio of SpO₂/FiO₂ to respiratory rate; R/I ratio, recruitment-to-inflation ratio

PP, the range of improvement in SpO₂ was from 1 to 34%, and the mean difference in intubation rates between patients with SpO₂ higher than 95% compared to those with less than 95% at 1 hour after PP was 46%.

Retucci et al.¹² in an observational study evaluated PP and lateral positioning in 26 patients on helmet continuous positive airway pressure (CPAP) and observed a high failure rate.

Table 2 shows the characteristics of the case series evaluating PP in patients with COVID-19, and all had used awake PP.^{23–31} The mean age of all 69 patients included in the case series was 58.0 years. The mean duration of single-PP session extended from 2 hours till 16 hours/day. The PaO₂/FiO₂ ratio, SpO₂, clinical improvement, and oxygen requirements were the most commonly used clinical outcomes.

Four case series involving 43 patients evaluating awake PP in SARS-CoV-2 were conducted in non-ICU areas,^{24,25,28,29} out of which, few were conducted among patients receiving helmet NIV.^{28–30} Ripollo-Gallardo et al.²⁸ and Bastoni et al.²⁹ in their retrospective series of 13 and 10 patients evaluated PP among patients on helmet NIV in the general ward and Emergency Department, respectively. Both studies showed improved oxygenation with PP; however, the latter in addition conducted lung ultrasonography (USG) and did not observe any change in recruitability with the PP. As far as the feasibility of PP with helmet NIV is concerned, it was reported as 92.3% by Ripollo-Gallardo et al.²⁸ and 60% by Bastoni et al.²⁹

Ng et al.²⁵ evaluated PP in 10 patients in the general ward with the FiO₂ requirement <0.5; three patients were later shifted to ICU where one died. The rest seven patients showed improvement in clinical symptoms. No PaO₂/FiO₂ ratio could be assessed due to the setting of the study. Out of five case series that were conducted in the ICU setup, three were conducted among patients receiving HFNC,^{23,26,27} one with helmet CPAP,³⁰ and one on non-rebreathing mask (NRBM).³¹

Table 3 shows the details of various case reports in this context.^{32–41} The mean duration of PP in these case reports ranged from 1 hour till 16–18 hours/day (Table 3).

Specific Subpopulation

Awake PP in ICU and Non-ICU Setups

Out of all 1,385 participants, 78.9% ($n = 1,093$) received awake PP in ICU and 21.0% ($n = 292$) received it in non-ICU areas, including emergency areas, wards, etc.

Awake PP in Pregnant Patient and Morbidly Obese

There has been little evidence regarding the use of PP in pregnant women with COVID-19. The only reported use of PP in pregnant patients with COVID-19 was found to be efficacious when combined with HFNC. However, the practical applicability or use of PP in the pregnant patient was a concern.²⁸ Recently, Paul et al. reported a morbidly obese (body mass index, 65 kg/m²) COVID-19 patient with obstructive sleep apnea and reported notable improvement in FiO₂ requirements titrated down to 0.4 within 1 hour of proning, which persisted even on return to supine position.²⁹

Awake PP along with HFNC

Nine articles that include two clinical studies,^{8,15} three case series,^{23,26,27} and five case reports^{34,36–39} including a total of 90 patients have evaluated awake PP along with HFNC in the management of COVID-19 pneumonia. This combination was

found to be feasible, helpful, and efficacious in terms of various oxygenation outcomes, for example, PaO₂/FiO₂, RR, SpO₂, and other clinical parameters, and also in a single case report on a pregnant patient with COVID-19 pneumonia.³⁶ However, there has been a lack of well-designed studies to validate this finding.

Awake PP with Helmet CPAP

Only one clinical study¹² and three case series^{28–30} including 59 patients have evaluated PP along with helmet CPAP. Retucci et al. observed a high failure rate with PP and lateral positioning in patients receiving helmet CPAP.¹² On the contrary, all the three case series found PP with helmet CPAP to be feasible and efficacious^{28–30}; however, the sustained improvement in oxygenation even after 12 hours of PP was documented only by Golestani et al.³⁰

Risk of Bias (Quality) Assessment

In order to assess the risk of bias of the included studies, the Cochrane Collaboration tool, namely ROBINS-I (“Risk of Bias In Non-randomized Studies—of Interventions”), was used. It is a tool for evaluating the risk of bias from nonrandomized studies utilizing interventions.⁶¹ The ROBINS-I assesses the risk of bias in seven domains: (1) bias due to confounding, (2) bias due to selection of participants, (3) bias in classification of interventions, (4) bias due to deviation from intended intervention, (5) bias due to missing data, (6) bias in the measurement of outcomes, and (7) bias in the selection of the reported result. Each aforementioned parameter of bias in each study will be scored as having low, medium, high, or unclear risk. The study with lower risk is deemed as a high-quality study. The risk of bias was independently assessed by GCT and ZA, and disagreements were resolved through discussion with MM. The overall judgment on the bias assessment following assessment of each domain of the included studies in the present systematic review as per the ROBINS-I tool has been found to have moderate to serious risk.⁶¹ The risk of bias was variable among different included studies. The weighted summary plot of different aforementioned biases among all nonrandomized studies^{6–22} was designed using robvis web app (Fig. 1).⁶²

DISCUSSION

The present review has summarized the current evidence of awake PP in patients with SARS-CoV-2, out of a total of 1,385 patients in whom awake PP was evaluated. Overall, the technique was found to be efficacious in terms of improvement in oxygenation in 78.9% ($n = 1,093$) of patients in ICU and 21.0% ($n = 292$) in non-ICU areas, including emergency areas, wards, etc. Awake PP along with HFNC was used in 90 patients and was found to be efficacious in all the cases. Awake PP was used in patients with helmet CPAP in 59 cases with inconclusive results. However, none of the studies have evaluated the optimal duration of awake PP; in the majority, the oxygenation parameters were evaluated within few minutes to only a few hours after PP, and no long-term outcomes were assessed.

PP reverses the compression atelectasis of the dorsal lungs due to heart and mediastinum and helps alveolar recruitment in the dorsal lung (now nondependent) by increasing the transpulmonary pressure leading to the homogenous distribution of ventilation across the lung.^{2,3} However, perfusion remains higher in the dorsal region due to higher production of nitric oxide (a potent vasodilator) in the endothelium of the dorsal lung leading to a

Table 2: Characteristics of the case series evaluating PP for COVID-19 pneumonia²³⁻³¹

| Authors | N/Gender | Age (yrs) | Setup | Initiation of therapy/ mode of oxygen therapy | Awake proning/ prone ventilation | Duration of proning | Outcome | Conclusion |
|---------------------------------------|-----------------|-------------------|----------------------|--|-------------------------------------|---|---|---|
| Xu et al. ²³ | 10 (50% males) | 50.2 | ICU | Severe hypoxemia on HFNC | Awake proning | Approx. 16 hr/day | Median PaCO ₂ ; PaO ₂ /FIO ₂ ratio | Median PaCO ₂ increased slightly [32.3(29.3–34.0) mm Hg vs 29.7 (28.0–32.0) mm Hg (p <0.001)] and significant increase in PaO ₂ /FIO ₂ after PP |
| Moghaddam et al. ²⁴ | 10 (70% males) | 41 | Non-ICU | Random selection | Awake proning | — | Clinical dyspnea; SpO ₂ before and after PP | Dyspnea decreased by 40% and SpO ₂ improved to 95.9% from 85.6% with PP |
| Ng et al. ²⁵ | 10 (80% males) | 60 | General ward | Patients requiring FIO ₂ <0.5 | Awake proning | 5 sessions/day with 1 hr/ session, each spaced 3 hr during the waking hours | Clinical symptoms; Weaning off oxygen; intubation | Low risk, low cost, and improvement in clinical symptoms reported with PP Limitation: PaO ₂ /FIO ₂ ratio not assessed |
| Despres et al. ²⁶ | 06 (100% males) | 60 | ICU | Patients on either HFNC (n = 3) or COT (n = 3) | Awake proning | 8.3 hr | PaO ₂ /FIO ₂ | A total of nine PP sessions in six patients. PP + HFNC in four sessions and PP + COT in five sessions. PaO ₂ /FIO ₂ ratio improved after four sessions, including three sessions with HFNC and one session with COT; intubation avoided in 50% patients |
| Damarla et al. ²⁷ | 10 (70% males) | 56 (range, 40–80) | ICU | HFNC (n = 4) and nasal cannula (n = 5) | Awake proning | 2 hr prone and supine alternately | Change in SpO ₂ and RR before and 1 hr after PP; intubation within 2 weeks | Median SpO ₂ increased from 94% (IQR, 91–95%) to 98% (IQR, 97–99%), median RR reduced from 31 (IQR, 28–39) to 22 (IQR, 18–25) breaths/min; 8 out of 10 did not require intubation |
| Ripoll-Gallardo et al. ²⁸ | 13 (85% males) | 66 | General ward | Patients on helmet NIV CPAP | Awake proning | Maintained as long as patient tolerated | PaO ₂ /FIO ₂ ; RR | Improved PaO ₂ /FIO ₂ compared to baseline in 12 patients (p = 0.003); no difference was found in the RR before and after PP (p = 0.20) |
| Bastoni et al. ²⁹ | 10 (80% males) | 73 | Emergency department | Patients on helmet NIV CPAP with no clinical improvement | Awake proning | 1 hr | PaO ₂ /FIO ₂ ; Lung USG | In 4 out of 10 patients, the attempt of PP failed; an improvement in PaO ₂ /FIO ₂ ratio from 68 ± 5 to 97 ± 8 mm Hg after 1 hr of PP in all; No change in B-line quantity and distribution in lung USG after 1 hr |
| Golestani Eraghi et al. ³⁰ | 10 | — | ICU | Patients with PaO ₂ /FIO ₂ ratio <150 and on helmet NIV | Awake proning | 9 hr | PaO ₂ /FIO ₂ ratio after 1 and 12 hr of PP | 60% patients had sustained improvement in PaO ₂ /FIO ₂ ratio after 1 hr; 30% of patients had delayed positive result, and one patient was intubated |
| Shukla et al. ³¹ | 24 | 54 | ICU | SpO ₂ <90% on NRBIM, PaO ₂ /FIO ₂ ratio <200 on ABG | — | — | Intubation rate | 37.5% failed trials of awake proning and required intubation 55.5% of these patients were successfully extubated Simplest, most resource-effective method for improving oxygenation |

N, number of patients; PP, prone positioning; NRBIM, non-rebreathing mask; HFNC, high flow nasal cannula, CPAP, continuous positive airway pressure; COT, conventional oxygen therapy; NIV, noninvasive ventilation; RR, respiratory rate; USG, ultrasonography

Table 3: Summary of the case reports evaluating PP for the management of COVID-19 pneumonia³²⁻⁴¹

| Authors | N | Set-up | Age (yrs)/gender | Initiation of therapy/ mode of oxygen therapy | Awake proning/ prone ventilation | Duration of proning | Outcome | Conclusion |
|----------------------------------|------|----------------------|--------------------------------|---|---|---|--|--|
| Sztanjbok et al. ³² | 2 | ICU | 43 and 37 (both males) | On NRBM | Awake proning | 8-10 hr | Need of oxygen (L/min), improvement in clinical symptoms, PaO ₂ /FiO ₂ ratio | Decrease in need of oxygen from 10 to 5 L/min; improvement in clinical symptoms and PaO ₂ /FiO ₂ |
| Elkattawys et al. ³³ | 1 | Emergency department | 36, male | Severe hypoxemia and on nasal cannula | Awake proning | At least 6-8 hr on nasal cannula (approx. 12 hr/day) | SpO ₂ on rest and on ambulation | After approx. 12 hr of PP, patient was taken off of nasal cannula with SpO ₂ >95% at rest and 90% on ambulation; however, tachycardia continued HFNC with self-proning leads to improvement in symptoms and oxygenation |
| Slessarev et al. ³⁴ | 1 | ICU | 68, male | Patient on HFNC | Awake proning | 16-18 hr/day including 8-10 hr in sleep | Clinical improvement | Improvement in SpO ₂ and reduction in RR observed between 10 min and 30 min after PP in both the cases |
| Cohen et al. ³⁵ | 2 | Non-ICU | 52, female and 40, male | Profound hypoxemia on oxygen via nasal cannula | Awake proning | 2-5 hr/day | Improvement in SpO ₂ and RR with PP | SpO ₂ and ABG parameters improved with PP; patient was weaned off HFNC and intermittent NIV and was discharged on day 24 after symptoms onset |
| Vibert et al. ³⁶ | 1 | ICU | 21 pregnant patient | 23 weeks of gestation, on HFNC | Awake proning | Lateralized for 2 hr period, that is, PP; right lateral, left lateral | Hemodynamic and ABG parameters before, during, and after PP | Within few hours of proning, the SpO ₂ improved and FiO ₂ requirement reduced to 0.4-0.5; obesity should not be a contraindication to PP |
| Paul et al. ³⁷ | 02 | ICU | 42, male and 35, male | First patient had severe hypoxemia on HFNC Second patient was morbidly obese | Early awake proning in first patient and late awake self-proning in second patient after extubation | 2-3 hr/session | SpO ₂ and oxygen requirement | The first two required 5 and 2 days of PP + HFNC, while the third patient was intubated after 4 days |
| Huang et al. ³⁸ | 03 | ICU | 55, male; 61, female; 61, male | Patients on HFNC | Awake proning | 4 sessions a day of 2 hr each | ROX index | CT findings suggestive of recruitment of alveoli along with a moderate decrease in the attenuation of the lesions in the lower lobes. PaO ₂ /FiO ₂ increased from 130 to 238 mm Hg with PP |
| Taboda et al. ³⁹ | 01 | Non-ICU | 71, female | Severe hypoxemia and on HFNC | Awake proning | CT scan in prone and supine position, duration of PP not mentioned | CT finding and PaO ₂ /FiO ₂ | The trial of PP resulted in a dramatic increase in peripheral oxygen saturations to 97% and decreased work of breathing |
| Alseoudy et al. ⁴⁰ | male | ICU | 2 | Following extubation for ARDS | Awake PP | 4 hr prone followed by 1 hr supine, these cycles for 4 days | Oxygen saturation | Significantly improves oxygenation in COVID-19 pneumonitis |
| Whittenmore et al. ⁴¹ | Male | ICU | 60 | On low flow oxygen therapy | Awake PP | > 18 hr/day | Oxygen saturation | |

N, number of patients; PP, prone positioning; HFNC, high flow nasal cannula; NRBM, non-rebreathing mask; CPAP, continuous positive airway pressure; COT, conventional oxygen therapy; NIV, noninvasive ventilation; ECMO, extracorporeal membrane oxygenation; RR, respiratory rate; V/Q scanning, ventilation/perfusion scanning; ET, endotracheal






Fig. 1: Risk of bias assessment using ROBINS-I tool⁶²

significant reduction in the relative shunt fraction along with the improvement in PaO₂/FiO₂. The role of prone ventilation in intubated ARDS patients has been established since the last few years.^{2,3} Extrapolating the evidence of PP in mechanically ventilated non-COVID ARDS patients, recently, even the Surviving Sepsis Campaign panel has advocated a trial of PP in mechanically ventilated COVID-19 patients with moderate to severe ARDS for a period of 12–16 hours.⁶³

In the present COVID-19 pandemic, the use of PP has been widely extended to awake patients in both ICU and non-ICU areas. Awake PP is an important adjuvant for improving oxygenation in ARDS along with other factors like FiO₂ delivered, mode of oxygen therapy, and other treatment protocols. HFNC has been known to increase the ventilator-free days and decrease the mortality in ICU patients. In the present systematic review, we observed a striking improvement in oxygenation with PP in patients who were receiving HFNC. We are also looking forward to the results of the ongoing *meta-trial* to investigate awake PP in COVID-19 patients undergoing HFNC.⁴⁵ However, with helmet NIV, its efficacy has been found to be contentious.

There have been concrete evidences regarding the optimal duration of prone ventilation in non-COVID ARDS^{2,3}; however, no study has assessed the optimal duration of awake PP since its inception has gained momentum in COVID-19 pandemic. The majority of the clinical studies evaluating awake PP in COVID-19 pneumonia have assessed the oxygenation as early as 5 minutes to the maximum of 1 to 3 hours after PP.^{6,9,11–13} The sustained improvement in oxygenation as assessed in a single study by Golestani et al. after 12 hours was observed in only 30% of patients.³⁰ In addition, only a few studies have utilized control group for the evaluation of awake PP.^{13,18,19} In all these studies, the assessment for improved oxygenation was undertaken as early as 1 hour^{13,18} till the end of day one.¹⁹ These studies' results highlighting the improvement in oxygenation following such a short duration of awake PP could possibly be implicated to the transient lung recruitment.⁵ This mandates the need to determine the optimal duration of awake PP along with the assessment of long-term clinical outcomes, for example, intubation rates and mortality.

The present systematic literature review is dealt with few limitations. Firstly, the studies included had small sample sizes and single centric data.

Secondly, except for one,¹³ all studies lacked the control group. Thirdly, considering the fact that early use of awake PP may improve the overall prognosis, the evidence regarding the efficacy and safety of the institution of PP in outside ICU setups has been found to be insufficient. Interestingly, a clinical study by Sartini et al.¹⁰ and two case series^{28,29} have evaluated PP in severely hypoxemic patients receiving NIV and helmet CPAP in non-ICU areas, a finding which cannot be related in developing countries with limited facilities during this pandemic times. Fourthly, there was a heterogeneous patient population in terms of the mode of oxygen therapy or respiratory support, duration of proning, treatment protocol, and severity of illness at the time of initiation of PP. Also, few studies displayed incomplete data, particularly the mode of oxygen therapy and duration of proning.

In conclusion, the literature available so far encourages the use of early awake self-proning in addition to its use in intubated patients in the management of SARS-CoV-2 infection. The short-term improvement in the oxygenation as reported in various trials could simply be a “recruitment maneuver” as the majority of the oxygenation outcome parameters were assessed between few minutes to 3 hours after PP in various studies. The overall evidence pertaining to the use of awake proning in the management of COVID-19 disease is not sufficient as there has been a lack of randomized controlled trial, and therefore, further well-designed multicentric studies with larger sample size and preferably with a control group are warranted to evaluate the PP as an adjunct in the management of COVID-19 pneumonia in terms of its safety, optimal duration of proning, and efficacy in improving oxygenation with individual modes of oxygen therapy.

ORCID

- Geetanjali T Chilkoti <https://orcid.org/0000-0002-2436-0444>
- Medha Mohta <https://orcid.org/0000-0003-4222-8428>
- Ashok K Saxena <https://orcid.org/0000-0003-1251-9320>
- Zainab Ahmad <https://orcid.org/0000-0002-5944-607X>
- Chhavi S Sharma <https://orcid.org/0000-0002-4852-2065>

REFERENCES

1. Gordon A, Rabold E, Thirumala R, Husain AA, Patel S, Cheema T. Prone positioning in ARDS. *Crit Care Nurs Q* 2019;42(4):371–375. DOI: 10.1097/CNQ.0000000000000277.

2. Munshi L, Del Sorbo L, Adhikari NKJ, Hodgson CL, Wunsch H, Meade MO, et al. Prone position for acute respiratory distress syndrome. A systematic review and meta-analysis. *Ann Am Thorac Soc* 2017;14(4):S280–S288. DOI: 10.1513/AnnalsATS.201704-343OT.
3. Bloomfield R, Noble D, Sudlow A. Prone position for acute respiratory failure in adults. *Cochrane Database Syst Rev* 2015;11:CD008095. DOI: 10.1002/14651858.CD008095.pub2.
4. Bamford P, Bentley A, Dean J, Whitmore D. ICS guidance for prone positioning of the conscious COVID patient. 2020.
5. Chad T, Sampson C. Prone positioning in conscious patients on medical wards: a review of the evidence and its relevance to patients with COVID-19 infection. *Clin Med (Lond)* 2020;20(4):e97–e103. DOI: 10.7861/clinmed.2020-0179.
6. Caputo ND, Strayer RJ, Levitan R. Early self-proning in awake, non-intubated patients in the emergency department: a single ED's experience during the covid-19 pandemic. *Acad Emerg Med* 2020;27(5):375–378. DOI: 10.1111/acem.13994.
7. Elharrar X, Trigui Y, Dols AM, Touchon F, Martinez S, Prud'homme E, et al. Use of prone positioning in nonintubated patients with COVID-19 and hypoxemic acute respiratory failure. *JAMA* 2020;323(22):2336–2338. DOI: 10.1001/jama.2020.8255.
8. Tu GW, Liao YX, Li QY, Dong H, Yang LY, Zhang XY, et al. Prone positioning in high-flow nasal cannula for COVID-19 patients with severe hypoxemia: a pilot study. *Ann Transl Med* 2020;8(9):598. DOI: 10.21037/atm-20-3005.
9. Coppo A, Bellani G, Winterton D, Di Pierro M, Soria A, Faverio P, et al. Feasibility and physiological effects of prone positioning in non-intubated patients with acute respiratory failure due to COVID-19 (PRON-COVID): a prospective cohort study. *Lancet Respir Med* 2020;8(8):765–774. DOI: 10.1016/S2213-2600(20)30268-X.
10. Sartini C, Tresoldi M, Scarpellini P, Tettamanti A, Carcò F, Landoni G, et al. Respiratory parameters in patients with COVID-19 after using noninvasive ventilation in the prone position outside the intensive care unit. *JAMA* 2020;323(22):2338–2340. DOI: 10.1001/jama.2020.7861.
11. Thompson AE, Ranard BL, Wei Y, Jelic S. Prone positioning in awake, nonintubated patients with COVID-19 Hypoxemic respiratory failure. *JAMA Intern Med* 2020;e203030. DOI: 10.1001/jamainternmed.2020.3030.
12. Retucci M, Aliberti S, Ceruti C, Santambrogio M, Tammaro S, Cuccarini F, et al. Prone and lateral positioning in spontaneously breathing patients with COVID-19 pneumonia undergoing noninvasive helmet CPAP treatment. *Chest* 2020;S0012-3692(20)31888-2. DOI: 10.1016/j.chest.2020.07.006.
13. Zang X, Wang Q, Zhou H, Liu S, Xue X; COVID-19 Early Prone Position Study Group. Efficacy of early prone position for COVID-19 patients with severe hypoxia: a single-center prospective cohort study. *Intensive Care Med* 2020;46(10):1–3. DOI: 10.1007/s00134-020-06182-4.
14. Jagan N, Morrow LE, Walters RW, Klein LP, Wallen TJ, Chung J, et al. The POSITIONED study: prone positioning in nonventilated coronavirus disease 2019 patients—a retrospective analysis. *Crit Care Explor* 2020;2(10):e0229. DOI: 10.1097/CCE.0000000000000229.
15. Hallifax RJ, Porter BM, Elder PJ, Evans SB, Turnbull CD, Hynes G, et al. Successful awake proning is associated with improved clinical outcomes in patients with COVID-19: single-centre high-dependency unit experience. *BMJ Open Respir Res* 2020;7(1):e000678. DOI: 10.1136/bmjresp-2020-000678.
16. Singh P, Jain P, Deewan H. Awake prone positioning in COVID-19 patients. *Indian J Crit Care Med* 2020;24(10):914–918. DOI: 10.5005/jp-journals-10071-23546.
17. Khanum I, Samar F, Fatimah Y, Safia A, Adil A, Kiren H, et al. Role of awake prone positioning in patients with moderate-to-severe COVID-19: an experience from a developing country. *Monaldi Arch Chest Dis* 2021;91(2):10. DOI: 10.4081/monaldi.2021.1561.
18. Sryma PB, Mittal S, Mohan A, Madan K, Tiwari P, Bhatnagar S, et al. Effect of proning in patients with COVID-19 acute hypoxemic respiratory failure receiving noninvasive oxygen therapy. *Lung India* 2021;38(Suppl.):S6–S10. DOI: 10.4103/lungindia.lungindia_794_20.
19. Kharat A, Dupuis-Lozeron E, Cantero C, Marti C, Groscurin O, Lolachi S, et al. Self-proning in COVID-19 patients on low-flow oxygen therapy: a cluster randomised controlled trial. *ERJ Open Res* 2021;7(1):00692–2020. DOI: 10.1183/23120541.00692-2020.
20. Tonelli R, Pisani L, Tabbi L, Comellini V, Prediletto I, Fantini R, et al. Early awake proning in critical and severe COVID-19 patients undergoing noninvasive respiratory support: a retrospective multicenter cohort study [published online ahead of print, 2021 Mar 22]. *Pulmonology* 2021;S2531-0437(21)00077-5. DOI: 10.1016/j.pulmoe.2021.03.002.
21. Nauka PC, Chekuri S, Aboodi M, Hope AA, Gong MN, Chen JT. A case-control study of prone positioning in awake and nonintubated hospitalized coronavirus disease 2019 patients. *Crit Care Explor* 2021;3(2):e0348. DOI: 10.1097/CCE.0000000000000348.
22. Dubosh NM, Wong ML, Grossestreuer AV, Loo YK, Sanchez LD, Chiu D, et al. Early, awake proning in emergency department patients with COVID-19. *Am J Emerg Med* 2020;S0735-6757(20)31105-0. DOI: 10.1016/j.ajem.2020.11.074.
23. Xu Q, Wang T, Qin X, Jie Y, Zha L, Lu W. Early awake prone position combined with high-flow nasal oxygen therapy in severe COVID-19: a case series. *Crit Care* 2020;24(1):250. DOI: 10.1186/s13054-020-02991-7.
24. Moghadam VD, Shafiee H, Ghorbani M, Heidarifar R. Prone positioning in management of COVID-19 hospitalized patients. *Rev Brasil Anestesiol* 2020;70(2):188–190. DOI: 10.1016/j.bjan.2020.05.001.
25. Ng Z, Tay WC, Ho CHB. Awake prone positioning for non-intubated oxygen dependent COVID-19 pneumonia patients. *Eur Respir J* 2020;56(1):2001198. DOI: 10.1183/13993003.01198-2020.
26. Despres C, Brunin Y, Berthier F, Pili-Floury S, Besch G. Prone positioning combined with high-flow nasal or conventional oxygen therapy in severe Covid-19 patients. *Crit Care* 2020;24(1):256. DOI: 10.1186/s13054-020-03001-6.
27. Damarla M, Zaeh S, Niedermeyer S, Merck S, Niranjan-Azadi A, Broderick B, et al. Prone positioning of nonintubated patients with COVID-19. *Am J Respir Crit Care Med* 2020;202(4):604–606. DOI: 10.1164/rccm.202004-1331LE.
28. Ripoll-Gallardo A, Grillenzoni L, Bollon J, Della Corte F, Barone-Adesi F. Prone positioning in non-intubated patients with COVID-19 outside of the intensive care unit: more evidence needed. *Disaster Med Public Health Prep* 2020;1–3. DOI: 10.1017/dmp.2020.267.
29. Bastoni D, Poggiali E, Vercelli A, Demichele E, Tinelli V, Iannicelli T, et al. Prone positioning in patients treated with non-invasive ventilation for COVID-19 pneumonia in an Italian emergency department. *Emerg Med J* 2020;37(9):565–566. DOI: 10.1136/emered-2020-209744.
30. Golestani-Eraghi M, Mahmoodpoor A. Early application of prone position for management of Covid-19 patients [published online ahead of print, 2020 May 26]. *J Clin Anesth* 2020;66:109917. DOI: 10.1016/j.jclinane.2020.109917.
31. Shukla U, Chavali S, Mukta P, Mapari A, Vyas A. Initial experience of critically ill patients with COVID-19 in Western India: a case series. *Indian J Crit Care Med* 2020;24(7):509–513. DOI: 10.5005/jp-journals-10071-23477.
32. Sztajnbock J, Maselli-Schoueri JH, Cunha de Resende Brasil LM, Farias de Sousa L, Cordeiro CM, Sansão Borges LM, et al. Prone positioning to improve oxygenation and relieve respiratory symptoms in awake, spontaneously breathing non-intubated patients with COVID-19 pneumonia. *Respir Med Case Rep* 2020;30:101096. DOI: 10.1016/j.rmcr.2020.101096.
33. Elkattawy S, Noori M. A case of improved oxygenation in SARS-CoV-2 positive patient on nasal cannula undergoing prone positioning. *Respir Med Case Rep* 2020;30:101070. DOI: 10.1016/j.rmcr.2020.101070.
34. Slessarev M, Cheng J, Ondrejicka M, Arntfield R; Critical Care Western Research Group. Patient self-proning with high-flow nasal cannula improves oxygenation in COVID-19 pneumonia. *Can J Anaesth* 2020;67(9):1288–1290. DOI: 10.1007/s12630-020-01661-0.
35. Cohen D, Wasserstrum Y, Segev A, Avaky C, Negru L, Turpashvili N, et al. Beneficial effect of awake prone position in hypoxaemic patients with COVID-19: case reports and literature review. *Intern*



- Med J 2020;10.1111/imj.14926. DOI: 10.1111/imj.14926. PMID: 32697030; PMCID: PMC7404489.
36. Vibert F, Kretz M, Thuet V, Barthel F, De Marcillac F, Deruelle P, et al. Prone positioning and high-flow oxygen improved respiratory function in a 25-week pregnant woman with COVID-19. *Eur J Obstet Gynecol Reprod Biol* 2020;250:257–258. DOI: 10.1016/j.ejogrb.2020.05.022.
 37. Paul V, Patel S, Royse M, Odish M, Malhotra A, Koenig S. Prone in non-intubated (PINI) in times of COVID-19: case series and a review. *J Intensive Care Med* 2020;35(8):818–824. DOI: 10.1177/0885066620934801.
 38. Huang CF, Zhuang YF, Liu J, Tay CK, Sewa DW. Rationale and significance of patient selection in awake prone positioning for COVID-19 pneumonia. *Eur Respir J* 2020;2002173. DOI: 10.1183/13993003.02173-2020.
 39. Taboada M, Rodríguez N, Riveiro V, Baluja A, Atanasoff PG. Prone positioning in awake non-ICU patients with ARDS caused by COVID-19. *Anaesth Crit Care Pain Med*. 2020;39(5):581–583. DOI:10.1016/j.accpm.2020.08.002.
 40. Als eoudy MM, Abo Elfetoh MA, Alrefaey AK. Awake proning of a 2-year-old extubated child with severe COVID-19 pneumonitis. *Anaesth Rep* 2020;8(2):183–186. DOI: 10.1002/anr3.12084.
 41. Whittemore P, Macfarlane L, Herbert A, Farrant J. Use of awake proning to avoid invasive ventilation in a patient with severe COVID-19 pneumonitis. *BMJ Case Rep* 2020;13(8):e236586. DOI: 10.1136/bcr-2020-236586.
 42. Jiang LG, LeBaron J, Bodnar D, Caputo ND, Chang BP, Chiricolo G, et al. Conscious proning: an introduction of a proning protocol for nonintubated, awake, hypoxic emergency department COVID-19 patients. *Acad Emerg Med* 2020;27(7):566–569. DOI: 10.1111/acem.14035.
 43. Bower G, He H. Protocol for awake prone positioning in COVID-19 patients: to do it earlier, easier, and longer. *Crit Care* 2020;24(1):371. DOI: 10.1186/s13054-020-03096-x.
 44. Longhini F, Bruni A, Garofalo E, Navalesi P, Grasselli G, Cosentini R, et al. Helmet continuous positive airway pressure and prone positioning: A proposal for an early management of COVID-19 patients. *Pulmonology* 2020;26(4):186–191. DOI: 10.1016/j.pulmo.2020.04.014.
 45. Li J, Pavlov I, Laffey JG, Roca O, Mirza S, Perez Y, et al. Meta-trial of awake prone positioning with nasal high flow therapy: Invitation to join a pandemic collaborative research effort. *J Crit Care* 2020;60:140–142. DOI: 10.1016/j.jcrr.2020.07.020.
 46. Bentley SK, Iavicoli L, Cherkas D, Lane R, Wang E, Atienza M, et al. Guidance and patient instructions for proning and repositioning of awake, nonintubated COVID-19 patients. *Acad Emerg Med* 2020;10.1111/acem.14067. DOI: 10.1111/acem.14067. PMID: 32597005; PMCID: PMC7361422.
 47. Nasa P, Azoulay E, Khanna AK, et al. Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method. *Crit Care* 2021;25(1):106. DOI: 10.1186/s13054-021-03491-y.
 48. Stilma W, Åkerman E, Artigas A, et al. Awake proning as an adjunctive therapy for refractory hypoxemia in non-intubated patients with COVID-19 acute respiratory failure: guidance from an international group of healthcare workers. *Am J Trop Med Hyg* 2021;104(5):1676–1686. DOI: 10.4269/ajtmh.20-1445.
 49. Lindahl SGE. Using the prone position could help to combat the development of fast hypoxia in some patients with COVID-19. *Acta Paediatr* 2020;109(8):1539–1544. DOI: 10.1111/apa.15382.
 50. Prasad M, Visrodia K. Should I prone non-ventilated awake patients with COVID-19? [published online ahead of print, 2020 Jun 30]. *Cleve Clin J Med* 2020;10. DOI: 10.3949/ccjm.87a.ccc050.
 51. Flynn Makic MB. Prone position of patients with COVID-19 and acute respiratory distress syndrome. *J Perianesth Nurs* 2020;35(4):437–438. DOI: 10.1016/j.jopan.2020.05.008.
 52. Sodhi K, Chanchalani G. Awake proning: current evidence and practical considerations. *Indian J Crit Care Med* 2020;24(12):1236–1241. DOI: 10.5005/jp-journals-10071-23684.
 53. Sen MK, Gupta N, Ish P, Kumar R, Yadav SR. Awake proning in Covid-19 pneumonia. *Infez Med*. 2020 Sep 1;28(3):453–455. PMID: 32920584.
 54. Raof S, Nava S, Carpati C, Hill NS. High-flow, noninvasive ventilation and awake (nonintubation) proning in patients with coronavirus disease 2019 with respiratory failure. *Chest* 2020;158(5):1992–2002. DOI: 10.1016/j.chest.2020.07.013.
 55. Khan S, Choudry E, Mahmood SU, Mulla AY, Mehwish S. Awake proning: a necessary evil during the COVID-19 pandemic. *Cureus* 2020;12(7):e8989. DOI: 10.7759/cureus.8989.
 56. Ghelichkhani P, Esmaeili M. Prone Position in Management of COVID-19 Patients; a Commentary. *Arch Acad Emerg Med*. 2020 Apr 11;8(1):e48. PMID: 32309812; PMCID: PMC7158870.
 57. McNicholas B, Cosgrave D, Giacomini C, Brennan A, Laffey JG. Prone positioning in COVID-19 acute respiratory failure: just do it? *Br J Anaesth* 2020;S0007-0912(20)30443-8. DOI: 10.1016/j.bja.2020.06.003.
 58. Munshi L, Fralick M, Fan E. Prone positioning in non-intubated patients with COVID-19: raising the bar. *Lancet Respir Med* 2020;8(8):744–745. DOI: 10.1016/S2213-2600(20)30269-1.
 59. Telias I, Katira BH, Brochard L. Is the prone position helpful during spontaneous breathing in patients with COVID-19? *JAMA* 2020;323(22):2265–2267. DOI: 10.1001/jama.2020.8539.
 60. Garg R. Conscious proning or mixed positioning for improving oxygenation-COVID-19 brings many changes! *Indian J Crit Care Med* 2020;24(10):893–894. DOI: 10.5005/jp-journals-10071-23624.
 61. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;355:i4919. DOI: 10.1136/bmj.i4919.
 62. McGuinness LA. robvis: An R Package and web application for visualizing risk-of-bias assessments. 2019. Retrieved from: <https://github.com/mcguinlu/robvis> [Accessed December 15, 2020].
 63. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). *Intensive Care Med* 2020;46(5):854–887. DOI: 10.1007/s00134-020-06022-5.